ClinicalTrials.gg
Status unknownNCT05562076PINTOUpdated Sep 30, 2022

Clinical Study of Focal Implant Used for Lower Extremity Post-angioplasty Dissection

An interventional study of the spot stent(ZENFLEX ® Pinto) system and the bare stent( Everflex) system in Peripheral Artery Disease, sponsored by Zhejiang Zylox Medical Device Co., Ltd.. Status unknown at 12 sites in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-30.

Sponsored by Zhejiang Zylox Medical Device Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Sep 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Peripheral Arterial Disease with a site in China — 32 open to participants now, 34 under way, 4 of them phase 3. Peripheral Arterial Disease · China.

Planned enrollment
16th of 53
224 · median 167
Started
2022
with 7 others
No phase
34 of 80
13 open now
Registered
47th of 80
by date
Lead sponsor
6 of 80
Zhejiang Zylox Medical Device Co., Ltd.

Among the 80 studies in Peripheral Arterial Disease with a site in China, this one is the 16th largest by planned enrollment of the 53 interventional ones that give a count, is one of 8 that started in 2022, is one of 34 with no phase, and was the 47th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

32 of the 80 studies in Peripheral Arterial Disease with a site in China are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Peripheral Arterial Disease with a site in China, or all of them as a file.
02

Study summary

This is a prospective, multicenter, randomized controlled trail using spot stenting to treat lower extremity post-angioplasty dissection.

03

Conditions studied

  • Peripheral Artery Disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 80 years,male or female
  2. Lower extremity atherosclerotic occlusive disease
  3. After PTA, angiography showed less than 30% residual stenosis of the target lesion (based on visual estimation), and there is one or more dissection(Type A-F)
  4. Subjects are able to understand the purpose of the study, demonstrate full compliance with the procedure and follow-up and sign

Exclusion criteria

Exclusion Criteria:

  1. The target lesion has been stented or previously treated with bypass surgery
  2. Acute thrombosis of the target vessel requires thrombolysis or thrombectomy, or has undergone local or systemic thrombolysis within 48 hours
  3. Cutting balloon, thrombectomy, plaque resection, brachytherapy, and laser therapy were planned
  4. More than 30% residual stenosis of the inflow artery (based on visual estimation) after treatment, or there is no outflow artery in the target limb
  5. The target lesion was too calcified to undergo PTA or the guide wire could not pass anterograde through the target lesion
  6. Planned amputation on the target limb
  7. Severe allergy to anticoagulant drugs, antiplatelet drugs, contrast media and Nitinol
  8. Uncontrollable infections
  9. Women who are pregnant or breastfeeding, or who plan to become pregnant during the duration of the trial
  10. Participating in clinical trials of any other drug or medical device and not yet out of the study
  11. Other circumstances not suitable for inclusion as judged by the investigator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
224 participants (estimated)

Study arms

  • Experimental
    ZENFLEX ® Pinto

    subjects using the spot stent(ZENFLEX ® Pinto) system

    Device: the spot stent(ZENFLEX ® Pinto) system

  • Active comparator
    Everflex

    subjects using the bare stent(Everflex) system

    Device: the bare stent( Everflex) system

Interventions

  • Devicethe spot stent(ZENFLEX ® Pinto) system

    the spot stent(ZENFLEX ® Pinto) system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography(DSA)

  • Devicethe bare stent( Everflex) system

    the bare stent( Everflex) system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography(DSA)

06

What researchers measure

Primary outcomes

  1. primary patency rate at 12 months after operation

    Time frame: 12 months

Secondary outcomes

  1. success rate of the device

    Time frame: Intraoperation

  2. success rate of the technique

    Time frame: post operation

  3. rate of CD-TLR

    Time frame: 6 months,12 months

  4. ABI

    Time frame: post operation, 6 months,12 months

  5. Rutherford classification

    Time frame: post operation, 6 months,12 months

  6. the incidence of major adverse events

    Time frame: 30 days, 6 months,12 months

  7. the rate of target limb major amputation

    Time frame: 30 days, 6 months,12 months

  8. the incidence of adverse events

    Time frame: Intraoperation, post operation, 30 days, 6 months,12 months

  9. the incidence of SAE

    Time frame: Intraoperation, post operation, 30 days, 6 months,12 months

  10. the rate of device defect

    Time frame: Intraoperation, 12 months

07

Study locations

12 sites
  • Xuanwu Hospital, Capital Medical University
    Beijing, China
    • Lianrui Guo · Contact
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, China
    • Chaowen Yu · Contact
  • Changzhou First People's Hospital
    Changzhou, China
    • Yufeng Zhu · Contact
  • Changzhou Second People's Hospital
    Changzhou, China
    • Yunfeng Zhu · Contact
  • The First Affiliated Hospital of Harbin Medical University
    Ha'erbin, China
    • Bing Liu · Contact
  • Anhui Provincial Hospital
    Hefei, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, China
    • Weimin Zhou · Contact
  • Nanjing Drum Tower Hospital
    Nanjing, China
    • Xiaoqiang Li · Contact
  • Affiliated Hospital of Qingdao University
    Qingdao, China
    • Mingjin Guo · Contact
  • Shanghai Ninth People's Hospital
    Shanghai, China
    • Xinwu Lu · Contact
  • Tianjin Medical University General Hospital
    Tianjin, China
    • Xiangchen Dai · Contact
  • North Jiangsu People's Hospital
    Yangzhou, China
    • Zhaolei Chen · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2022; primary completion for Feb 2024, 15 months later.

Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 15 months is below that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2022
First posted
Sep 30, 2022
StartEst.
Nov 2022
Primary completionEst.
Feb 2024
CompletionEst.
Feb 2025
Last update
Sep 30, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05562076
Lead sponsor
Zhejiang Zylox Medical Device Co., Ltd.
Responsible party
Sponsor
First posted
Sep 30, 2022
Start date
Nov 2022 (estimated)
Primary completion
Feb 2024 (estimated)
Completion
Feb 2025 (estimated)
Last update
Sep 30, 2022

Study contacts

jie Liang
Contact
jie.liang@zyloxmedical.com
13819565660
Xiaoqiang Li
principal investigator · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion